{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-23-000042","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.336425+00:00","generated_at":"2026-06-08T09:17:17.776962+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024","bullets":["Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.","Auryxia net product revenue $40.1M (Q3 2022: $42.0M); FY 2023 guidance reaffirmed at $170-175M.","Vadadustat NDA resubmission accepted; PDUFA date set for March 27, 2024 for anemia in dialysis CKD.","Vadadustat approved in 36 countries including Australia and Taiwan; five posters at Kidney Week 2023.","Modified Pharmakon loan: principal payments deferred to Oct 2024, maturity extended to March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-23-000042","json":"https://secwatch.observer/filing/0001517022-23-000042.json","markdown":"https://secwatch.observer/filing/0001517022-23-000042.md","text":"https://secwatch.observer/filing/0001517022-23-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/0001517022-23-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/akba-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:17:17.776962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"778ee0b19d1d38350a0af441e38b38241bb631c6","claim":"Akebia Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $42.0 million, net income $14.5 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $42.0 million for the third quarter of 2023, compared to $48.7 million for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000042/0001517022-23-000042-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$42.0 million"},{"label":"Net income","value":"$14.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}